Phase I clinical trial design in cancer drug development

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 684-692

  Eisenhauer, Elizabeth A ^a   O'Dwyer, P J ^a   Christian, M ^a   Humphrey, J S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,3 DIMETHYL 1 TRIAZENO)BENZOIC ACID; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; ADOZELESIN; BRYOSTATIN; GIROLLINE; IRINOTECAN; NEMORUBICIN; PENCLOMEDINE; PYRAZINAMIDE; SATRAPLATIN; TELOXANTRONE; TETRAPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033973070     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.684     Document Type: Article

References (12)

1. Dent SF, Eisenhauer EA: Phase I trial design: Are new methodologies being put into practice? Ann Oncol 7:561-566, 1996
2. Arbuck SG: Workshop on Phase I design: Ninth NCI EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol 7:567-573, 1996
3. Von Hoff DD, Turner J: Response rates, duration of response and dose response effects in phase I trials of antineoplastics. Invest New Drugs 9:115-122, 1991
4. Collins JM, Zaharko DS, Dedrick RL, et al: Potential roles for preclinical pharmacology in phase I trials. Cancer Treat Rep 70:73-80, 1986
5. Collins JM, Grieshaber CK, Chabner BA: Pharmacologically guided phase I trials based upon preclinical development. J Natl Cancer Inst 82:1321-1326, 1990
6. Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: Efficient dose escalations with overdose control. Stat Med 17:1103-1120, 1998
7. Rogatko A, Babb J: Escalation With Overdose Control (EWOC). Http://www.fccc.edu/users/rogatko
8. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
9. O'Quigley J: Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 48:853-862, 1992
10. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
11. Eckhardt SG, Siu LL, Clark G, et al: The continual reassessment method (CRM) for dose escalation in phase I trials in San Antonio does not result in more rapid study completion. Proc Am Soc Clin Oncol 18:163a, 1999 (abstr 627)
12. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997